Problems at a contract manufacturing organisation have scuppered Eli Lilly’s hopes of a timely FDA approval for lebrikizumab, its IL-13 inhibitor for the treatment of atop
Biogen says it is the first drugmaker in the US to get FDA approval for a biosimilar of Roche’s $3 billion blockbuster product Actemra.
In today’s dynamic pharmaceutical landscape, having a high level of strategic alignment and the flawless execution of this strategy is crucial for life sciences companies aiming to establis
MSD has been granted a priority review by the FDA for its pulmonary arterial hypertension (PAH) candidate sotatercept, setting up a decision on the would-be blockbuster by
Can you imagine a world where pharmaceutical marketing was as thrilling as a sloth hosting a speed dating event?
Editor's Picks
